Resum

Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.

Idioma originalAnglès
Pàgines (de-a)19-27
Nombre de pàgines9
RevistaJournal of Neuroimmunology
Volum326
Data online anticipada7 de nov. 2018
DOIs
Estat de la publicacióPublicada - 15 de gen. 2019

Fingerprint

Navegar pels temes de recerca de 'Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study'. Junts formen un fingerprint únic.

Com citar-ho